Dr. Sagar A. Patel, MD
Claim this profileEmory Saint Joseph's Hospital
Studies Prostate Cancer
Studies Skin Cancer
5 reported clinical trials
16 drugs studied
Area of expertise
1Prostate Cancer
Stage I
Stage II
2Skin Cancer
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Sagar A. Patel, MD is currently running
Pegylated Interferon Alfa-2a
for Myelofibrosis
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Recruiting1 award Phase 1
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Recruiting2 awards Phase 31 criteria
More about Sagar A. Patel, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sagar A. Patel, MD has experience with
- Leuprolide
- Relugolix
- Abiraterone Acetate
- Radiation Therapy
- Pegylated Interferon Alfa-2a
- Photon
Breakdown of trials Sagar A. Patel, MD has run
Prostate Cancer
Skin Cancer
Acute Myeloid Leukemia
Myelofibrosis
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sagar A. Patel, MD specialize in?
Sagar A. Patel, MD focuses on Prostate Cancer and Skin Cancer. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Sagar A. Patel, MD currently recruiting for clinical trials?
Yes, Sagar A. Patel, MD is currently recruiting for 2 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Sagar A. Patel, MD has studied deeply?
Yes, Sagar A. Patel, MD has studied treatments such as Leuprolide, Relugolix, Abiraterone Acetate.
What is the best way to schedule an appointment with Sagar A. Patel, MD?
Apply for one of the trials that Sagar A. Patel, MD is conducting.
What is the office address of Sagar A. Patel, MD?
The office of Sagar A. Patel, MD is located at: Emory Saint Joseph's Hospital, Atlanta, Georgia 30342 United States. This is the address for their practice at the Emory Saint Joseph's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.